



13th International Congress on Spondyloarthritides

7 - 9 September 2022
Ghent, Belgium

www.spa-congress.org



Final Programme

Presidents

Francesco Ciccia (Italy)
Walter P. Maksymowych (Canada)

Local Organising Committee

Dirk Elewaut (Belgium)
Filip Van den Bosch (Belgium)

Honorary Scientific Committee

Eric Veys (Belgium – Founder)
Herman Mielants (Belgium – Founder)
Paul Bowness (UK)
Jürgen Braun (Germany)
Matthew Brown (Australia)
Robert Colbert (USA)
Robert Inman (Canada)
Marjatta Leirisalo-Repo (Finland)
Jose A. Lopez de Castro (Spain)
John Reveille (USA)
Martin Rudwaleit (Germany)
Joachim Sieper (Germany)
Desirée van der Heijde (The Netherlands)
David Yu (USA)

Scientific Committee

Xenofon Baraliakos (Germany)
Maxime Breban (France)
Rubén Burgos Vargas (Mexico)
Laura Coates (UK)
Félicie Costantino (France)
Maria-Antonietta D’Agostino (France)
Atul Deodhar (USA)
Joerg Ermann (USA)
Lianne Gensler (USA)
Nigil Haroon (Canada)
Robert Landewé (The Netherlands)
Rik Lories (Belgium)
Helena Marzo-Ortega (UK)
Percival Sampaio-Barros (Brazil)
Jose Scher (USA)
Georg Schett (Germany)

Dear colleagues and friends,

Welcome to the **13th International Congress on Spondyloarthritis**, which will take place on the 7 – 9 September 2022 in the beautiful city of Gent as a wholly in-person meeting. The congress has grown over the years to become the premier international event in the field of the Spondylarthritides. Indeed, the attendance has almost quadrupled since 1998 to include scientists, medical doctors, allied health professionals, pharmaceutical industry representatives and people affected by these conditions from all over the world.

The success of the Gent congress has been underpinned by the quality of the scientific contributions including the state-of-the-art lectures given by carefully chosen guest speakers and selected abstract presenters.


The programme for the 2022 congress will offer a wide range of topics including basic and clinical translational research, genetics, imaging and therapeutics. A highly regarded part of the meeting are the poster sessions which provide the perfect frame for stimulating and interactive multidisciplinary exchanges among attendees. This year will mark the first year that we will have poster tours for each of the sessions. In addition, we have planned lively debates on highly controversial topics in clinical and basic science which promise to be educational as well as entertaining.

The “Gent Oration” - aimed to honor a scientist or clinician who is recognized internationally as having made major contributions throughout their career - will be given by Professor Jürgen Braun.

The social programme including the Walking Dinner at the Opening Reception, Gala dinner and Farewell Drink are sure to give you the opportunity to catch up with old and new friends and enjoy the magic of Gent.

As co-presidents of the **13th International Congress on Spondyloarthritis** we would like to welcome you to this exciting occasion which we are sure will once again, provide the best platform for vibrant scientific and clinical discussions in all aspects of these fascinating group of diseases.

Francesco Ciccia and Walter P. Maksymowych
Congress Presidents



12.50 **Welcome Address**
 Francesco Ciccia and Walter P. Maksymowych,
 Congress Presidents

SESSION 1: State-of-the-Art Symposium

13.00 INV1 **A risk benefit analysis of JAKi in rheumatology**
 Jasvinder Singh, USA

13.30 INV2 **JAKi-mechanism of action: What explains their efficacy in SpA?**
 Massimo Gadina, USA

SESSION 2: Basic Science: Stromal Cells and Innate Immunity in SpA Pathogenesis

14.00 INV3 **The stromal code in SpA**
 Rik Lories, Belgium

14.20 INV4 **Stromal cells: Commanders of joint inflammation, or innocent bystanders?**
 Eric Gracey, Belgium

14.40 INV5 **MIF-neutrophil-bone axis in AS pathogenesis**
 Nigil Haroon, Canada

15.00 Coffee Break and **Poster Session A**

SESSION 3: Innovations in Core Outcomes

16.00 INV6 **The Updated ASAS Core Set: What are the controversies and remaining unmet needs?**
 Victoria Navarro-Compan, Spain

16.20 INV7 **Novel biomarker technologies for axSpA: Lessons learned from RA and PsA**
 Hussein Al-Mossawi, UK

Selected Oral Presentations I: Treatment of SpA

16.40 01 **ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update**
 Sofia Ramiro, Leiden & Heerlen, The Netherlands

16.55 02 **Bimekizumab in patients with active non-radiographic and radiographic axial spondyloarthritis: Efficacy and safety up to week 24 from the BE MOBILE phase 3 studies**
 Xenofon Baraliakos, Bochum, Germany

17.10 03 **Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on progression of structural damage in the spine over two years in patients with ankylosing spondylitis (consul): An open-label, randomized controlled, multicenter trial**
 Fabian Proft, Berlin, Germany

17.25 04 **Recapture rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: Results at week 104 from a randomized placebo-controlled withdrawal study**
 Robert Landewé, Amsterdam, The Netherlands

17.40 **Grand Debate**
 Moderator: Francesco Ciccia, Italy

INV8 **Motion: The primary etiopathological lesion in axial spondyloarthritis is enthesitis**
 Dennis McGonagle, UK

INV9 **Counter motion: The primary etiopathological lesion in axial spondyloarthritis is marrow-centric**
 Walter P. Maksymowych, Canada

18.30 Opening Reception and Walking Dinner



The Ghent SpA Oration

Chair: Walter P. Maksymowych, Canada

- 08.30 INV10 **What happened in the field of axial spondyloarthritis in the last decades? A personal view**
Jürgen Braun, Germany

Selected Oral Presentations II: Epidemiology and Imaging

- 09.30 05 **The prevalence of inflammatory back pain and HLA-B27 in a large population-based cohort in the Netherlands**
Stan Kieseke, Groningen, The Netherlands

- 09.45 06 **A machine learning pipeline for prediction of bone marrow oedema along the sacroiliac joints on magnetic resonance imaging**
Joris Roels, Ghent, Belgium

- 10.00 07 **An AI-based algorithm for automatic detection of erosion and ankylosis on CT images of the sacroiliac joints: Multicentre development and validation**
Lennart Jans, Ghent, Belgium

- 10.15 08 **Does gender influence outcome measures similarly in patients with spondyloarthritis? Results from the ASAS-perSpA study**
Diego Benavent, Madrid, Spain

- 10.30 Coffee Break and **Poster Session B**

SESSION 4: Gut Corner

- 11.30 INV11 **Gut ache: The outcome of dysbiosis in the joint**
Ranjeny Thomas, Australia

- 11.50 INV12 **Investigating the microbiota in gut and joint disease using transgenic & germ-free mouse technology**
Lars Vereecke, Belgium

- 12.10 INV13 **Decrypting the conundrum of intestinal inflammation in AS pathogenesis**
Daniele Mauro, Italy

- 12.30 **Lunch**

Keynote Basic Science Lecture

Chair: Francesco Ciccia, Italy

- 13.30 INV14 **Advances in fibroblast biology that impact spondyloarthritis**
Chris Buckley, UK

Selected Oral Presentations III: Pathogenesis of SpA

- 14.10 09 **MIF is an important mediator in SpA associated gut inflammation in SKG mouse**
Shaghayegh Foroozan Boroojeni, Toronto, Canada

- 14.25 010 **High dimensional immunophenotyping of peripheral blood populations by mass cytometry in axial spondyloarthritis**
Claudia Worth, Oxford, UK

- 14.40 011 **Mechanical loading-induced BHLHE40 promotes inflammatory arthritis**
Eric Gracey, Ghent, Belgium

- 14.55 012 **Single cell analysis of ankylosing spondylitis synovial T cells identifies CD8 and TREG clonal expansion and phenotypic patterns of tissue adaptation**
Davide Simone, Oxford, UK


- 15.10 013 **Reduced frequency of RORγT regulatory T cells in axial spondyloarthritis: Effect of secukinumab treatment**
Addison C. Pacheco, Toronto, Canada

- 15.25 Coffee Break and **Poster Session C**

- 16.30 **Grand Debate**
Moderator: Walter P. Maksymowych

- Motion: Axial inflammation in PsA is distinct from axSpA**
INV15 (PRO) Dafna Gladman, Canada
INV16 (CON) Robert Landewé, The Netherlands

- 17.15 End of day 2



Session 5: Therapeutics Corner

- 08.30 INV17 **Priority targets from early phase trials in SpA and PsA**
Iain McInnes, UK
- 08.50 INV18 **Common pitfalls in the analysis and interpretation of axSpA RCTs**
Alexandre Sepriano, Portugal
- 09.10 INV19 **Emerging technologies in drug delivery: The promise of nanotherapeutics**
Hua Pan, USA
- Flash Oral Presentations IV: Treatment, Epidemiology, and Imaging**
- 09.30 O14 **Do fatty lesions explain the association between inflammation and new syndesmophytes in patients with radiographic axial spondyloarthritis?**
Roos Stal, Leiden, The Netherlands
- 09.37 O15 **A phase 2 randomized controlled trial of the Janus Kinase (JAK) inhibitor filgotinib in patients with noninfectious uveitis**
Robin Besuyen, Leiden, The Netherlands
- 09.44 O16 **Comorbidities in early psoriatic arthritis: Belgian prospective METAPSA cohort**
Alla Ishchenko, Antwerp, Belgium
- 09.51 O17 **Bimekizumab in BDMARD-naïve patients with psoriatic arthritis: 24-week efficacy & safety from BE OPTIMAL, a phase 3, multicentre, randomised, placebo-controlled, active reference study**
Robert Landewé, Amsterdam, The Netherlands
- 09.58 O18 **MRI spinal lesions in patients without MRI or radiographic lesions in the sacroiliac joints typical of axial spondyloarthritis**
Walter Maksymowych, Edmonton, Canada
- 10.05 O19 **Pathogenicity of IL-17 producing cells in HLA-B27 transgenic rat model of spondyloarthritis**
Marie Beaufrière, Paris & Boulogne-Billancourt, France

- 10.15 Coffee Break and **Poster Session D**

Session 6: Genetics Corner

- 11.15 INV20 **Family studies in Axial Spondyloarthritis: What have we learnt?**
Félicie Costantino, France
- 11.40 INV21 **Genomic dissection of the causes of ankylosing spondylitis**
Matthew Brown, UK
- 12.05 INV22 **From GWAS to function: Using functional genomics to identify the mechanisms underlying ankylosing spondylitis**
Matteo Vecellio, UK

Session 7: Imaging Corner

- 12.20 INV23 **What does molecular imaging tell us about tissue reparation in axSpA?**
Andreas Ramming, Germany
- 12.40 INV24 **Trials and tribulation of CT in axSpA: Is there a final verdict?**
Torsten Diekhoff, Germany
- 13.00 INV25 **Artificial intelligence, machine learning and radiomics for imaging in rheumatology**
Berend Stoel, The Netherlands
- 13.35 Farewell Reception



Poster session A is during the coffee break of 15.10 – 16.10 hrs on Wednesday, September 7. The presenters of the posters P1 through P24 are requested to be present at their posters.

- P1 Work participation and productivity is unaffected in Belgian spondyloarthritis patients compared to the general population: Data from the Belgian Inflammatory Arthritis and Spondylitis cohort (Be-GIANT)**
De Craemer A., Deroo L., Renson T., Desimpele I., Delmez L., Decuman S., Janssens X., Boonen A., Elewaut D., Carron P., Van den Bosch F. (Belgium & The Netherlands)
- P2 Development of international consensus on a standardized image acquisition protocol for diagnostic evaluation of the sacroiliac joints by MRI – an ASAS-SPARTAN collaboration**
Lambert R., Baraliakos X., Bernard S., Carrino J., Diekhoff T., Eshed I., Hermann K-G., Herregods N., Jaremko J.L., Jans L., Jurik A.G., O'Neill J., Reijnierse M., Tuite M., Maksymowych W.P. (Canada, Germany, USA, Israel, Belgium, Denmark & The Netherlands)
- P3 Magnetic resonance imaging characteristics of spine and sacroiliac joints in patients with psoriatic arthritis and axial manifestations**
Baraliakos X., Pournara E., Coates L.C., Blanco R., O'Brien E., Schulz B., Navarro-Compán V., Landewé R. (Germany, Switzerland, UK, Spain, Ireland & The Netherlands)
- P4 Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in axial spondyloarthritis - Results from fifteen countries in the European Spondyloarthritis (EuroSpA) Research Collaboration Network**
Hellamand P., Van de Sande M.G.H., Ørnbjerg L.M., Klausch T., Nurmohamed M.T., Van Vollenhoven R.F., Nordström D., Hokkanen A., Santos M.J., Vieira-Sousa E., Loft A.G., Glintborg B., Hetland M.L., Lindström U., Wallman J.K., Michelsen M., Ciurea A., Nissen M.J., Codreanu C., Mogosan C., Macfarlane G.J., Jones G.T., Laas K., Rotar Z., Tomsic M., Castrejon I., Pombo-Suarez M., Gudbjornsson B., Geirsson A.J., Kristianslund E.K., Vencovský J., Nekvindová L., Gulle S., Zengin B., Østergaard M., Van der Horst- Bruinsma I.E. (Sweden, Denmark, Czech Republic, Turkey, Norway, Switzerland, Portugal, Finland, Romania, Slovenia, Iceland, The Netherlands, Spain, Italy & UK)

- P5 Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis - Results from thirteen countries in the European Spondyloarthritis (EuroSpA) Research Collaboration Network**
Hellamand P., Van de Sande M.G., Midtbøll Ørnbjerg L.M., Klausch T., Trokovic N., Sokka-Isler T., Santos M.J., Vieira-Sousa E., Loft A.G., Glintborg B., Østergaard M., Lindström U., Wallman J.K., Michelsen B., Möller B., Micheroli R., Codreanu C., Mogosan C., Laas K., Rotar Z., Tomsic M., Castrejon I., Pombo-Suarez M., Gudbjornsson B., Love T.J., Fagerli K.M., Pavelka K., Závada J., Kenar G., Yarkan H., Hetland M.L., Van der Horst- Bruinsma I.E. (Sweden, Denmark, Czech Republic, Turkey, Norway, Switzerland, Portugal, Finland, Romania, Slovenia, Iceland, The Netherlands, Spain & Italy)
- P6 Comparison of established and new, preliminarily proposed ASAS cut-offs for inflammatory MRI lesions in the sacroiliac joints in axial spondyloarthritis and implications for recruitment in clinical studies**
Baraliakos X., Machado P.M., Bauer L., Hoepken B., Kim M., Kumke T., Tham R., Rudwaleit M. (Germany, UK & USA)
- P7 Bimekizumab in bDMARD-naïve patients with psoriatic arthritis: Interim analysis of inhibition of radiographic structural progression at 16 weeks of treatment in BE OPTIMAL, a phase 3, multicentre, randomised, placebo-controlled, active reference study**
Landewé R.B.M., Asahina A., Coates L.C., Mease P.J., Ritchlin C.T., Tanaka Y., Ink B., Assudani D., Bajracharya R., Coarse J., Gladman D.D. (The Netherlands, Japan, UK, USA & Canada)
- P8 Bimekizumab in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: 16-week efficacy & safety from BE COMPLETE, a phase 3, multicentre, randomised placebo-controlled study**
Merola J.F., McInnes I.B., Ritchlin C.T., Mease P.J., Landewé R.B.M., Asahina A., Tanaka Y., Warren R.B., Gossec L.C., Gladman D.D., Behrens F., Ink B., Assudani D., Bajracharya R., Coarse J., Coates L.C. (USA, UK, The Netherlands, Japan, France, Canada & Germany)
- P9 The impact of MRI slice thickness on the detection of spinal syndesmophytes in axial spondyloarthritis**
Klavdianou K., Mewes A.D., Tsiami S., Sewerin P., Baraliakos X. (Germany & Greece)



- P10 Pain response in psoriatic arthritis patients treated with guselkumab is driven predominantly by inflammation-independent effects**
Mease P.J., Soriano E.R., Chakravarty S.D., Rampakakis E., Shawi M., Nash P., Rahman P. (USA, Argentina, Canada & Australia)
- P11 Genetic and molecular distinctions between axial psoriatic arthritis and ankylosing spondylitis**
Kavanaugh A., Baraliakos X., Gao S., Chen W., Sweet K., Chakravarty S.D., Song Q., Shawi M., Behrens F., Rahman P. (USA, Germany & Canada)
- P12 Radiographic progression from non-radiographic to radiographic axial spondyloarthritis: Results from a 5-year multicountry prospective observational study**
Podubnyy D., Sieper J., Akar S., Muñoz-Fernández S., Haibel H., Diekhoff T., Protopopov M., Altmaier E., Ganz F., Inman R.D. (Germany, Turkey, Spain, Switzerland & Canada)
- P13 Is radiographic axial involvement associated with syndesmophyte development after 2 years in PsA patients**
de Hooge M., Ishchenko A., Steinfeld S., Nzeusseu Toukap A., Elewaut D., Lories R., Van den Bosch F., de Vlam K. (Belgium)
- P14 Tissue tropism in T cell dependent regulatory pathways controlling TNF driven SpA-like joint and gut pathology**
Venken K., Decruy T., De Craemer A., Vlieghe C., Jarlborg M., Mortier C., Coudenys J., Dove D., Klimowicz A., Gilis E., Hoorens A., Lobaton T., De Roock S., Sparwasser T., Nabozny G., Jacques P., Elewaut D. (Belgium, USA, The Netherlands & Germany)
- P15 IL-23 induced GDF15 contributes to trabecular bone loss, but does not affect skin, gut or joint inflammation**
Van der Cruyssen R., Gaublomme D., Dumas E., Stappers F., Coudenys J., Decruy T., Vereecke L., Gracey E., Elewaut D. (Belgium)
- P16 Deep immune profiling of cytotoxic T cells (CTL) from patients with ankylosing spondylitis revealed a subset of CTL Co-expressing PD-1 and TIGIT that resists immune exhaustion**
Tang M., Pacheco A.C., Qaiyum Z., Lim M., Inman R.D. (Canada)
- P17 Validation of the SPARCC MRI-RETIC E-Tool for increasing scoring proficiency of MRI lesions in axial spondyloarthritis**
Maksymowych W.P., Hadsbjerg A.E.F., Østergaard M., Micheroli R., Pedersen S.J., Ciurea A., Vladimirova N., Nissen M.J., Bubova K., Wichuk S., De Hooge M., Mathew A.J., Pintaric K., Gregová M., Snoj Z., Wetterslev M., Gorican K., Paschke J., Eshed I., Lambert R.G. (Canada, Denmark, Switzerland, Czech Republic, Belgium, Slovenia & Israel)

- P18 Elevated complement proteins in patients with axSpA compared with appropriate controls with low back pain with and without SpA-features**
Mistegaard C.E., Troldborg A., Hansen A., Thiel S., Jurik A.G., Kiil R.M., Christiansen A.A., Schiøttz-Christensen B., Hendricks O., Loft A.G. (Denmark)
- P19 Semiquantitative assessment of synovitis on US-guided synovial membrane biopsies is contingent on disease phase and predictive of treatment response in naive to treatment psoriatic arthritis**
Bruno D., Tulusso B., Gessi M., Di Mario C., Gigante M., Petricca L., Perniola S., Paglionico A., Varriano V., Peluso G., Bui L., Elmesmari A., Somma D., D'Agostino M.A., Kurowska Stolarska M., Gremese E., Alivernini S. (Italy & UK)
- P20 Direct and indirect effect of TNF inhibitors on spinal mobility in people with axial spondyloarthritis (axSpA) and the mediator role of disease activity**
Pinto A.S., Yao B., Harris C., Hayward R., Keat A., Machado P.M. (Portugal & UK)
- P21 IL-4 and IL-13 modulate entheseal IL-23 production and blockade with dupilumab is associated with emergent Th17 type diseases**
Bridgwood C., Wittmann M., Macleod T., Watad A., Newton D., Bhan K., Amital H., Damiani G., Giryas S., Bragazzi N.L., McGonagle D. (UK, Israel, Italy & Canada)
- P22 Single cell analysis of the response of axial spondyloarthritis to TNFi therapy**
Jin L., Curion F., Penkava F., Chen L., Attar M., Bowden R., Bowness P., Sansom S.N. (UK, Germany & Australia)
- P23 Prevalence of axSpA in patients treated for chronic back pain in chiropractic clinics: The Oregon Chiropractic Axial Spondyloarthritis Study (ORCAS) – An interim analysis**
Kiwalkar S., Bhalerao S., Nguyen K.P., Quinn R.P., Perham D., Malatestinic W., Bolce R., Hunter T., Khurana P., Deodhar A. (USA)
- P24 Comparison of sacroiliac CT findings in patients with and without Psoriatic Arthritis: results of the CASIPSA Study**
Fakih O., Ramon A., Prati C., Ornetti P., Wendling D., Verhoeven F. (France)



Poster session B is during the coffee break of 10.30 – 11.30 hrs on Thursday, September 8. The presenters of the posters P25 through P48 are requested to be present at their posters.

- P25 Psoriasis, without rheumatological manifestations, is associated with structural changes of the sacroiliac joint, a controlled study using CT scan**
Leriche T., Fakih O., Aubin F., Chouk M., Prati C., Wendling D., Verhoeven F. (France)
- P26 Effect of tofacitinib and glucocorticoids on intestinal permeability, epithelial damage and bacterial translocation in rat adjuvant-induced arthritis**
Hecquet S., Totoson P., Tournier M., Prati C., Wendling D., Demougeot C., Verhoeven F. (France)
- P27 Immunological differences between psoriatic arthritis patients who are tumor necrosis factor inhibitor-naïve and who have inadequate response to tumor necrosis factor inhibitors**
Siebert S., Coates L.C., Schett G., Raychaudhuri S.P., Chen W., Gao S., Chakravarty S.D., Shawi M., Lavie F., Theander E., Neuhold M., Kollmeier A.P., Xu X.L., Rahman P., Mease P.J., Deodhar A. (UK, Germany, USA, France, Sweden, Switzerland & Canada)
- P28 Effect of guselkumab on serum biomarkers in psoriatic arthritis patients with inadequate response or intolerance to tumor necrosis factor inhibitors: Results from the COSMOS study**
Schett G., Chen W., Gao S., Chakravarty S.D., Shawi M., Lavie F., Theander E., Neuhold M., Coates L.C., Siebert S. (Germany, USA, France, Sweden, Switzerland & UK)
- P29 Patient characteristics and clinical assessments associated with progression from non-radiographic axial spondyloarthritis to ankylosing spondylitis**
Kieskamp S.C., Wilbrink R., Siderius M., Maas F., Wink F., Bos R., Bootsma H., Arends S., Spoorenberg A. (The Netherlands)
- P30 Treatment decisions in axial spondyloarthritis are more than treat to target**
Bolt J.W., Aalbers C.J., Walet L., Van Mens L.J.J., Van Denderen J.C., Van der Horst-Bruinsma I.E., Van Baarsen L.G.M., Landewé R., Van de Sande M.G.H. (The Netherlands)
- P31 Effect of cigarette smoking on inflammatory arthritis in Curdlan administered SKG mice**
Park M-C., Lee J-H., Lee E-J., Chang E-J., Kim Y-G. (Korea)

- P32 Oral and gut microbial profile in ankylosing spondylitis treated with secukinumab: Chronic disease related dysbiosis**
Grau García E., Rodenes Gavidia A.M., Fragio Gil J.J., González Mazario R., Muñoz Martínez P., Mas Sánchez L., Riesco Barcena C., Huaylla Quispe A.V., Leal Rodríguez S., Pávez Perales C., De la Rubia M., Cánovas Olmos I., González Puig L., Ivorra Cortés J., Martínez Cordellat I., Nájera Herranz C., Negueroles Albuixech R., Oller Rodríguez J., Ortiz-Sanjuán F., Vicens Bernabéu E., Lamelas Cabello A., Chenoll Cuadros E., Román Ivorra J.A. (Spain)
- P33 Association of demographic and clinical characteristics of patients with familial Mediterranean fever and axial spondyloarthritis with the M694V mutation**
Kiracı M., Bilgin E., Duran E., Farisogulları B., Bolek E.C., Yardımcı G.K., Özsoy Z., Ayan G., Sandal Uzun G., Akbaba T.H., Balci Peynircioglu B., Karadağ O., Akdoğan A., Apraş Bilgen Ş., Kiraz S., Ertenli., Kalyoncu U., Kilic L. (Turkey)
- P34 Co-expression of IL17F and IL17A secretion by enthesal resident T-cells and circulating T-cells is preferentially from the CD4 T-cell subset**
McDermott N.L., Bridgwood C., MacLeod T., Khan A., Milner P., Loughenbury P., Rao A., Dunsmuir R., McGonagle D., Mahroof A. (UK)
- P35 Radiographic spinal damage in psoriatic arthritis patients compared to SpA patients**
de Hooge M., Ishchenko M., DeCramer A-S., Steinfeld S., Nzeusseu Toukap A., Elewaut D., Lories R., de Vlam K., Van den Bosch F. (Belgium)
- P36 Antibodies to two novel peptides in new onset axial spondyloarthritis**
Ruytinx P., Vandormael P., Luyten E., De Craemer A.S., Van den Bosch F., Elewaut D., Somers V. (Belgium)
- P37 Antibodies of different isotypes to novel peptides in early axial spondyloarthritis**
Ruytinx P., Vandormael P., Luyten E., Vanhoof J., Geusens P., Somers V. (Belgium)
- P38 Efficacy and safety of non-pharmacological and non-biological therapy: A systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis**
Ortolan A., Webers C., Sepriano A., Falzon L., Baraliakos X., Landewé R., Ramiro S., van der Heijde D., Nikiphorou E. (The Netherlands, Italy, Portugal, UK & Germany)



- P39 Upregulation of innate inflammatory pathways in peripheral blood during the preclinical phase of axial spondyloarthritis**
Hammoura I., Bolt J.W., Jongejan A., de Jong H.M.Y., van Gaalen F.A., van der Heijde D., van Baarsen L.G.M., van de Sande M.G.H. (The Netherlands)
- P40 SPARCC, MASES, LEI and MEI indexes capture different patients with enthesitis in axial spondyloarthritis, peripheral spondyloarthritis and psoriatic arthritis**
Granados R.E.M., Ladehesa Pineda M.L., Puche Larrubia M.A., Dougados M., Collantes Estevez E., López Medina C. (Spain & France)
- P41 Treating spondyloarthritis early: Does it matter? Results from a systematic literature review**
Capelusnik D., Benavent D., van der Heijde D., Landewé R., Poddubnyy D., van Tubergen A., Falzon L., Navarro-Compán V., Ramiro S. (Argentina, Spain, The Netherlands, Germany & UK)
- P42 Plasma exosomal miRNAs in ankylosing spondylitis: Prospects for biomarkers**
Tavasolian F., Inman R.D. (Canada)
- P43 Ankylosing spondylitis and the risk of atherosclerotic cardiovascular diseases: A two-sample Mendelian randomization study**
Chen S.H., Gu J.R. (China)
- P44 A deep learning framework for MRI detection of active inflammatory and structural changes in the sacroiliac joint consistent with axial spondyloarthritis**
Bressem K.K., Adams L.C., Proft F., Hermann K-G.A., Diekhoff T., Spiller L., Niehues S.M., Makowski M.R., Hamm B., Protopopov M., Rios Rodriguez V., Haibel H., Rademacher J., Torgutalp M., Lambert R.G., Baraliakos X., Maksymowych W.P., Vahldiek J.L., Poddubnyy D. (Germany & Canada)
- P45 Treat-to-target strategy implementation in spondyloarthritis patients of real-world clinical practice remains limited despite high disease activity levels: A cross-sectional single-center study**
Flouri I.D., Avgoustidis N., Eskitzis A., Repa A., Pateromichelaki K., Pitsigavdaki S., Diamantopoulou S., Nikoloudaki M., Terizaki M., Bertsias G., Sidiropoulos P. (Greece)


- P46 Safety of guselkumab in patients with active psoriatic arthritis who are bio-naïve or TNFi-experienced: Pooled results from 4 randomized clinical trials through 2 years**
Rahman P., Boehncke W-H., Mease P.J., Gottlieb A.B., McInnes I.B., Neuhold M., Shawi M., Wang Y., Sheng S., Bergmans P., Kollmeier A.P., Theander E., Yu J., Leibowitz E., Marrache A.M., Coates L.C. (Canada, Switzerland, USA, UK, The Netherlands & Sweden)
- P47 Low rates of radiographic progression with 2 years of guselkumab (TREMFA®), a selective inhibitor of the interleukin-23p19 subunit: Results from a phase 3, randomized, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis**
Mease P.J., Gottlieb A.B., McInnes I.B., Rahman P., Kollmeier A.P., Xu X.L., Jiang Y., Sheng S., Shawi M., Chakravarty S.D., Lavie F., van der Heijde D. (USA, UK, Canada & The Netherlands)
- P48 Consistent long-term guselkumab efficacy across psoriatic arthritis domains irrespective of baseline patient characteristics**
McInnes I.B., Tesser J., Schioppa E., Merola J.F., Chakravarty S.D., Rampakakis E., Shiff N.J., Kollmeier A.P., Xu X.L., Shawi M., Lavie F., Bird P., Mease P.J. (UK, USA, Canada, France, Australia)



Poster session C is during the coffee break of 15.25 – 16.30 hrs on Thursday, September 8. The presenters of the posters P49 through P72 are requested to be present at their posters.

- P49 Examining the impact of disease activity on quality of life in women with axial spondyloarthritis**
Maguire S., Family Wilson F., Gallagher P., O'Shea F. (Ireland)
- P50 In radiographic axial spondyloarthritis spinal mobility measures correlate well with the whole spine CT Syndesmophyte Score (CTSS)**
Stal R.A., Ramiro S., Baraliakos X., Braun J., Reijnierse M., van den Berg R., van der Heijde D., van Gaalen F.A. (The Netherlands & Germany)
- P51 Low dose computed tomography Hounsfield units: A reliable methodology for assessing changes in vertebral bone density in radiographic axial spondyloarthritis**
Marques M.L., Pereira da Silva N., van der Heijde D., Reijnierse M., Braun J., Baraliakos X., van Gaalen F.A., Ramiro S. (The Netherlands, Portugal & Germany)
- P52 Is inflammation-driven bone loss associated with two-year bone formation at the same vertebra in axial spondyloarthritis? – A multilevel analysis from the SIAS Cohort**
Marques M.L., Pereira da Silva N., van der Heijde D., Stal R., Baraliakos X., Braun J., Reijnierse M., Bastiaenen C., van Gaalen F.A., Ramiro S. (The Netherlands, Portugal & Germany)
- P53 Increased neutrophil frequency in lymph nodes of patients with psoriatic arthritis**
Bolt J.W., O'Byrne A.M., Van Ansenwoude C.M.J., Semmelink H.F.J., Maas M., Van de Sande M.G.H., Van Baarsen L.G.M. (The Netherlands)
- P54 Six years treatment with TNF- α inhibitors does not lead to prolonged hypermineralization as assessed by bone turnover markers in patients with ankylosing spondylitis**
Siderius M., Spooenberg A., Van der Veer E., Kroese F.G.M., Arends S. (The Netherlands)
- P55 The course of bone mineral density during 8 years of treatment with TNF- α inhibitors in patients with ankylosing spondylitis**
Siderius M., Spooenberg A., Wink F.R., Arends S. (The Netherlands)

- P56 Long-term follow-up of starting and switching from original adalimumab to adalimumab biosimilar: Real-world data in axial spondyloarthritis**
Pinto A.S., Flora K., Matharu D., Isaacs A., Machado P.M. (Portugal & UK)
- P57 Predictors of remission in patients with axial spondyloarthritis: A systematic literature review**
Pinto A.S., Farisogullari B., Machado P.M. (Portugal, Turkey & UK)
- P58 Differentiation between IL-6 and IL-17 pathway inhibition in relationship with clinical outcomes in non-biological DMARD-IR and biological DMARD-IR psoriatic arthritis patients treated with upadacitinib in SELECT-PsA 1 and SELECT-PsA 2 studies**
Cai F., Sornasse T., Ruzek M., Fang Y., Kato K., Wung P., McInnes I. (USA & UK)
- P59 Effect of guselkumab (TREMFA®), a selective IL-23p19 inhibitor, on axial-related endpoints in patients with active PsA: Results from a phase 3, randomized, double-blind, placebo-controlled study through 2 years**
Mease P.J., Helliwell P.S., Gladman D.D., Poddubnyy D., Baraliakos X., Chakravarty S.D., Kollmeier A.P., Xu X.L., Sheng S., Xu S., Shawi M., van der Heijde D., Deodhar A. (USA, UK, Canada, Germany & The Netherlands)
- P60 Efficacy and safety of biological DMARDs: A systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis**
Webers C., Ortolan A., Sepriano A., Falzon L., Baraliakos X., Landewé R., Ramiro S., van der Heijde D., Nikiphorou E. (The Netherlands, Italy, Portugal, UK & Germany)
- P61 Filgotinib treatment results in reduction of inflammatory and matrix remodeling biomarkers associated with disease in patients with ankylosing spondylitis**
Maksymowych W., Tian Y., Xu J., Barchuk W., Galien R., Besuyen R., Liu Y., Malkov V., Hertz A. (Canada, USA, France & The Netherlands)
- P62 Serum Granulocyte-Monocyte Colony Stimulating Factor (GM-CSF) is increased in patients with active ankylosing spondylitis (AS) and persists despite anti-TNF treatment**
Papagoras C., Tsiami S., Chrysanthopoulou A., Mitroulis I., Baraliakos X. (Greece & Germany)



- P63 Earlier clinical response predict low rates of radiographic progression in bio-naive active psoriatic arthritis patients receiving guselkumab treatment**
Mease P.J., Gottlieb A.B., Ogdie A., McInnes I.B., Chakravarty S.D., Rampakakis E., Kollmeier A.P., Xu X.L., Shawi M., Lavie F., Kishimoto M., Rahman P. (USA, UK, Canada, France & Japan)
- P64 Spinal radiographic progression and its association with progression to ankylosing spondylitis in patients with non-radiographic axial spondyloarthritis**
Kieskamp S.C., Siderius M., Wilbrink R., Maas F., Wink F., Bos R., Bootsma H., Arends S., Spoorenberg A. (The Netherlands)
- P65 Platelet-derived growth factor B is a key element in the pathological bone formation of ankylosing spondylitis**
Jo S., Lee S.H., Park J., Nam B., Kim H., Kang H.-D., Youn J., Lee S., Kim T.-J., Sung I.-H., Choi S.H., Park Y.-S., Inman R.D., Kim T.-H. (Republic of Korea & Canada)
- P66 Immunoglobulins are upregulated in psoriatic arthritis skin lesions but not in psoriasis skin lesions**
Johnsson H., Cole J., Siebert S., McInnes I.B., Graham G. (UK)
- P67 Utility of the subchondral bone attenuation coefficient of the sacroiliac margins to differentiate spondyloarthritis and osteitis condensans ilii**
Terrier A., Fakhri O., Chouk M., Prati C., Wendling D., Aubry S., Verhoeven F. (France)
- P68 Whole blood transcriptional changes following treatment with filgotinib in patients with ankylosing spondylitis**
Poddubnyy D., Liu Y., Barchuk W., Besuyen R., Galien R., Tian Y., Malkov V., Hertz A. (Germany, USA, The Netherlands & France)
- P69 What does it mean – a good response to NSAIDs? A systematic comparison of patients with axial spondyloarthritis and controls with chronic back pain**
Baraliakos X., Redeker I., Bergmann E., Tsiami S., Braun J. (Germany)
- P70 Guselkumab (TREMFA®) maintains resolution of dactylitis and enthesitis in patients with active psoriatic arthritis: Results through 2 years from a phase 3 study**
Rahman P., McInnes I.B., Deodhar A., Schett G., Mease P.J., Shawi M., Cua D., Sherlock J.P., Kollmeier A.P., Xu X.L., Jiang Y., Sheng S., Ritchlin C.T., McGonagle D. (Canada, UK, USA & Germany)

- P71 Screening for the early identification of psoriatic arthritis with axial involvement (AXPSA) in a cohort of Italian patients affected by psoriasis (ATTRACT): Preliminary results of a cross-sectional study**
Benfaremo D., Paci V., Cimaroli I., Agostinelli A., Sordillo R., Offidani A.M., Moroncini G., Proft F., Poddubnyy D., Luchetti Gentiloni M.M. (Italy & Germany)
- P72 No change in serum levels of bone turnover markers corrected for age and gender during the first year of secukinumab treatment in patients with ankylosing spondylitis**
Siderius M., Arends S., Wink F.R., Spoorenberg A. (The Netherlands)



Poster session D is during the coffee break of 10.15 – 11.15 hrs on Friday, September 9. The presenters of the posters P73 through P96 are requested to be present at their posters.

- P73 The ASAS core outcome set for axial spondyloarthritis**
Navarro-Compán V., Boel A., Boonen A., Mease P., Dougados M., Kiltz U., Landewé R., van der Heijde D. (Spain, The Netherlands, USA, France & Germany)
- P74 Impact of spine ankylosis on bone fragility evaluated on CT-scan in patients with ankylosing spondylitis**
Morizot C., Fauny M., Allado E., Pinzano-Watrin A., Chary-Valckenaere I., Loeuille D. (France)
- P75 Are $\alpha\beta7+$ $\gamma\delta$ T cells prone for the IL-17 and IL-22 secretion in spondyloarthritis?**
Gómez-Mosqueira R., Domínguez-López M.L., Rivas-Hernández N., Meza-Olguín G., Burgos-Vargas R., Arriaga-Pizano L.A., Romero-López J.P. (Mexico)
- P76 Increased expression of B cell receptor signalling genes in patients with ankylosing spondylitis**
Wilbrink R., Verstappen G.M.P.J., Spoorenberg J.P.L., Kroese F.G.M. (The Netherlands)
- P77 Real-world persistence and treatment patterns in psoriatic arthritis patients treated with anti-IL17 therapy: The PERFIL-17 study**
Joven B., Fito Manteca C., Rubio E., Raya E., Pérez A., Hernandez R., Manrique S., Núñez M., Díaz S., Trancho L., Garcia de Vicuña R. (Spain)
- P78 Treatment with upadacitinib in refractory psoriatic arthritis - Multicenter study of 51 patients of clinical practice**
Galíndez-Agirregoikoa E., Prieto D., Rubio E., Joven B., Rusinovich O., Belzunegui J., Ventín C., Melerio R.I.B., Jovaní V., Busquets-Pérez N., Pérez A., Ivorra R., Almodóvar R.I., García de Vicuña R., González T., Ramos A., Pávez, Ortiz F., Rico E., Emperiale V., Calvo I., Pérez S., García-Vivar M.L., Gorostiza I., González Gay M.A., Blanco R. (Spain)
- P79 Impact of patient and disease characteristics on global functioning and health in patients with axial spondyloarthritis: A Bayesian Network analysis of data from an early axSpA cohort**
Redeker I., Landewe R., van der Heijde D., Ramiro S., Boonen A., Dougados M., Braun J., Kiltz U. (Germany, The Netherlands & France)

- P80 Development through co-creation of a personalized, multimodal, physiotherapist-led, work-oriented intervention to increase workability in working people with axial spondyloarthritis or rheumatoid arthritis**
Bakker N.F., Knoop J., Hutting N., Heerkens Y.F., Engels J.A., Staal J.B., van der Leeden M., Boonen A., Tiggeloven J.B.W., Schuur N.J., Vliet Vlieland T.P.M., van Weely S.F.E. (The Netherlands)
- P81 Predictors of sustained remission in people with axial spondyloarthritis treated with biologic drugs**
Farisogullari B., Yardımcı G.K., Bilgin E., Bölek E.Ç., Sarıyıldız E., Ayan G., Aksoy Z., Sandal Uzun G., Ekici M., Unaldı E., Kılıç L., Akdoğan A., Karadağ O., Apraş Bilgen Ş., Kiraz S., Ertenli İ., Kalyoncu U., Machado P.M. (Turkey & UK)
- P82 Multi-biologic resistant anterior uveitis in the context of spondyloarthritis**
Kougkas N., Dimitroulas T., Avgoustidis N. (Greece)
- P83 Korean treatment recommendations for the patients with axial spondyloarthritis**
Seo M.R., Yeo J., Park J.W., Lee Y.-A., Lee J.H., Kang E.H., Ji S.M., Kwon S.-R., Kim S.-K., Kim T.-J., Kim T.-H., Kim H.W., Park M.-C., Shin K., Lee S.-H., Lee E.Y., Cha H.-S., Shim S.C., Yoon Y., Lee S.H., Lim J.H., Baek H.J. (Republic of Korea)
- P84 Distribution of inflammatory/degenerative/ ambiguous lesions on conventional lumbar lateral radiographs in psoriatic arthritis patients**
Ayan G., Sadic A., Kilic L., Kalyoncu U. (Turkey)
- P85 Electrical treatment on sleep disturbance within autoimmune diseases patients and its effectiveness on immunologic factors**
Jiaoshi Z., Jieruo G. (China)
- P86 Adipsin and resistin levels are increased in serum of spondyloarthritis patients**
Bernal-Alferes B., Meza-Olguín G., Burgos-Vargas R., Romero-López J.P. (Mexico)
- P87 Electrocardiographic disturbances in psoriatic arthritis - A case-controlled study**
Azevedo S.F., Carvalho S., Mazedo C., Silva S.P., Barcelos A. (Portugal)



- P88 Machine learning classification of vitamin D levels in spondyloarthritis patients**
Castro Corredor D., Calvo Pascual L.A., Garrido Merchán E.C. Ramírez Huaranga M.A., Paulino Huertas M. (Spain)
- P89 Machine learning model of the ultrasound index of MASEI enthesitis and other variables of disease activity in patients with spondyloarthritis**
Castro Corredor D., Calvo Pascual L.A., Ramírez Huaranga M.A., Garrido Merchán E.C., Paulino Huertas M. (Spain)
- P90 Do lateral and AP radiographs tell different story in patients with psoriatic arthritis?**
Ayan G., Sadic A., Kilic L., Kalyoncu U. (Turkey)
- P91 Development and validation of a screening tool for spondyloarthritis in Sub-Saharan Africa: SpASSS questionnaire**
Lebughe P.L., Westhovens R., Malemba J.J., de Vlam K. (Democratic Republic of the Congo & Belgium)
- P92 Self-reported physical activity in patients with axSpA: Adherence to public health recommendations and association with health status in two Dutch cohorts**
Carbo M., Hilberdink B., Paap D., Wink F., Vliet Vlieland T., van Weely S., Spoorenberg A., Arends S. (The Netherlands)
- P93 Applicability of the MASEI index in enthesitis and its association with other indices/serological markers of activity in patients with spondyloarthritis**
Castro Corredor D., Calvo Pascual L.A., Garrido Merchán E.C, Ramírez Huaranga M.A., Paulino Huertas M. (Spain)
- P94 How is early spondyloarthritis defined in the literature? Results from a systematic review**
Benavent D., Capelusnik D., van der Heijde D., Landewé R., Poddubnyy D., van Tubergen A., Falzon L., Ramiro S., Navarro-Compán V. (Spain, Argentina, The Netherlands, Germany & UK)
- P95 Pelvis radiography findings and progression rates in patients with psoriatic arthritis under biologic treatment**
Ayan G., Sadic A., Kilic L., Kalyoncu U. (Turkey)
- P96 Clinical characteristics of late-onset ankylosing spondylitis in Korea**
Kim M.H., Yeo J. (Republic of Korea)

- P97 Translation and cross-cultural adaptation of coping with rheumatic stressors (CORS) into Turkish language**
Ayan G., Ramiro S., Pimentel-Santos F.M., Van Lankveld W., Kilic L. (Turkey, The Netherlands & Portugal)
- P98 Work abandonment in patients with ankylosing spondylitis under 45 years of age**
Burlui A.M., Cardoneanu A., Macovei L.A., Bratoiu I., Richter P., Codrianu A., Parvu M., Rezus E. (Romania)
- P99 Re-induction with certolizumab pegol after secondary loss of response is a valid therapeutic strategy in axial spondyloarthritis and psoriatic arthritis**
Conesa Mateos A., Bedoya Sanchis D., Lozano Saez A., Ángel Belmonte Serrano M. (Spain)
- P100 Adapting to living with axial spondyloarthritis: Results from the European map of axial spondyloarthritis (EMAS)**
Garrido-Cumbrera M., Poddubnyy D., Bundy C., Makri S., Mahapatra R., Correa-Fernández J., Christen L., Delgado-Domínguez C.J., Navarro-Compán V. (Spain, Germany, UK, Cyprus & Switzerland)
- P101 Assessment of the impact of axial spondyloarthritis on patient's social life: Results of the European map of axial spondyloarthritis (EMAS)**
Garrido-Cumbrera M., Navarro-Compán V., Bundy C., Mahapatra R., Makri S., Correa-Fernández J., Christen L., Delgado-Domínguez C.J., Poddubnyy D. (Spain, UK, Cyprus, Switzerland & Germany)
- P102 Role of patient organizations in implementation of recommended non-pharmacological treatment modalities in spondyloarthritis: Evidence for the effectiveness of self-management strategies**
Meyer-Olson D., Hoepfer K., Hammel L., Lieb S., Haehle A., Kiltz U. (Germany)
- P103 Differences in early-onset vs. Late-onset psoriatic arthritis: Data from the RESPONDIA and REGISPONSER studies**
Puche-Larrubia M.A., Ladehesa-Pineda L., López-Montilla M.D., Collantes-Estévez E., López-Medina C. (Spain & France)
- P104 Experience of clinics specialized in multidisciplinary care (MCC) in psoriatic arthritis (APS) in different health systems in Mexico**
Casasola-Vargas J., Vázquez-González D., Mendoza-Fuentes A., López Tello A., Chiapas-G K., Estrada-Aguilar L., Castro-Colin Z., Miranda-Hernández D., Godínez Aldrete L. (Mexico)



- P105 Health-related quality of life measures in axial spondyloarthritis of recent diagnosis**
 Vicens Bernabeu E., Huaylla Quispe A.V., Riesco Barcena C., Grau García E., Pávez Perales C., Leal Rodríguez S., Mas Sánchez L., Muñoz Martínez P., Ortiz-Sanjuán F., Fragío Gil J.J., Oller Rodríguez J.E., Martínez Cordellat I., Negueroles Albuixech R., De la Rubia Navarro M., Nájera Herranz C., Cánovas Olmos I., Ivorra Cortés J., González Puig J., Román Ivorra J.A. (Spain)
- P106 Axial spondyloarthritis, age and male gender impact COVID vaccination adverse events more than rheumatoid arthritis**
 Keeling S.O., Pan B., Hutchings E., Wichuk S., Osman M., Singh A., Sonpar A., Swartz I., Maksymowych W.P. (Canada)
- P107 Less than expected impact of rheumatoid arthritis and axial spondyloarthritis disease on COVID severity**
 Keeling S.O., Pan B., Hutchings E., Wichuk S., Osman M., Singh A., Sonpar A., Swartz I., Maksymowych W.P. (Canada)
- P108 Prevalence of obesity and its relationship with the level of joint activity in patients with psoriatic arthritis**
 Moreno Morales J., Albaladejo Paredes G., Pérez González A., Rodríguez Martínez F., Cogolludo Campillo V. (Spain)
- P109 The practical utility of superb microvascular imaging technique in evaluation of enthesitis: Pictorial case series**
 Seskute G., Butrimiene I. (Lithuania)
- P110 Tumor necrosis factor receptor associated factor 1 (TRAF1) is a great therapeutic target for RA patients as seen by its opposing effects on monocytes and T lymphocytes**
 Akram A., Inman R., Abdul-Sater A. (Canada)
- P111 Real-life efficacy of upadacitinib in patients with psoriatic arthritis: Preliminary results of a multicentric Italian study**
 Paci V., Benfaremo D., Gigli M., Sordillo R., Chimenti M.S., Ramonda R., Moroncini G., Luchetti M.M. (Italy)
- P112 Turkish translation and cross-cultural adaptation of the modified short questionnaire to assess health-enhancing physical activity (MSQUASH)**
 Ayan G., Ramiro S., Pimentel-Santos F.M., Spoorenberg A., Arends S., Kilic L. (Turkey, The Netherlands & Portugal)
- P113 Electrocardiographic findings in axial spondylarthritis compared to psoriatic arthritis - A cross-sectional study**
 Azevedo S.F., Carvalho S., Mazedo C., Silva S.P., Barcelos A. (Portugal)

Congress	Until 30/06	As of 01/07	As of 01/09
Participant MD	€ 600,00	€ 650,00	€ 700,00
Student/researcher non-MD with Abstract*	€ 350,00	€ 400,00	€ 400,00
Industry Participant	€ 800,00	€ 850,00	€ 900,00
Congress Dinner on Thursday 8 September	€ 75,00	€ 75,00	€ 75,00

The registration fee includes:

- Access to all lectures
- Access to the exhibition
- Coffee breaks and lunches as mentioned in the programme
- Opening Reception & Walking Dinner on Wednesday 7 September
- Farewell Reception on Friday 9 September

Separate registration for the Congress Dinner on Thursday 8 September is mandatory.


Participation into the Opening Reception & Walking Dinner and the Farewell Reception is free but pre-registration is mandatory.

Payment

Payment is to be made by credit card. Only VISA and MasterCard are accepted.

Cancellations

Cancellations received no later than 15 August, entitle registered persons to a 50% refund. In order to cancel your registration and/or hotel booking please contact Sarah Volckaert: sarah@medicongress.com.



A number of hotel rooms have been booked at special group rates, including breakfast and VAT.

The rates are available on the website (<https://spa-congress.org/hotel-accommodation>) and are only valid for reservations made through Medicongress.

Housing requests are filled in order of receipt. If the hotel of your choice is filled, you will be assigned to another hotel. Hotel availability cannot be guaranteed after August 15.

Any requests for hotel accommodation must be accompanied by a credit card number, in order to secure the room. This credit card will not be charged by the organisers but only serves as a reservation guarantee. Participants will have to pay their hotel room and personal expenses at the reception of the hotel. In case of late cancellation or no show, the room will be charged on the credit card.

A hotel confirmation will be sent by email after receipt of the registration form and housing request and payment of the registration fee.

Venue

De Bijloke
Bijlokekaai 7
9000 Gent
<https://www.bijloke.be/>

De Bijloke is located in the city centre, within walking distance from the hotels.

Dates

Wednesday 7 September – Friday 9 September 2022

Language

The official congress language is English.

Exhibition

A medical exhibition is held on the occasion of the Congress. Access is free for registered participants. The exhibition is not accessible for non-MDs.

Catering

Coffee breaks and lunches will be served in the exhibition area/

WiFi

Free WiFi is offered to all participants and exhibitors. The WiFi access code will be available onsite.


Liability

Neither the organisers nor Medicongress accept liability for damages and/ or losses of any kind which may be incurred by Congress participants during the Congress. Participants are advised to take out insurance against loss, accidents or damage which could be incurred during the Congress.

Organisation and Administration

MEDICONGRESS
Noorwegenstraat 49
B-9940 Evergem, Belgium
Phone: +32 (0)9 218 85 85
Email: congresses@medicongress.com

medicongress
conference & association management



Platinum Sponsors

abbvie



Lilly

Gold Sponsor



Silver Sponsor

